Open AccessLocalization of tamoxifen in human breast cancer tumors by MALDI mass spectrometry imaging
Author(s) -
Végvári Ákos,
Shavkunov Alexander S.,
Fehniger Thomas E.,
Grabau Dorthe,
Niméus Emma,
MarkoVarga György
Publication year - 2016
Publication title -
clinical and translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2001-1326
DOI - 10.1186/s40169-016-0090-9
Subject(s) - tamoxifen , breast cancer , mass spectrometry imaging , estrogen receptor , stroma , medicine , pathology , mass spectrometry , estrogen , chemistry , cancer research , cancer , immunohistochemistry , chromatography
Background Tamoxifen is used in endocrine treatment of breast cancer to inhibit estrogen signaling. A set of stratified ER‐positive and ER‐negative tumor sections was subjected to manual deposition of tamoxifen solution in order to investigate its spatial distribution upon exposure to interaction within thin tissue sections. Methods The localization of tamoxifen in tumor sections was assessed by matrix assisted laser deposition/ionization mass spectrometry imaging. The images of extracted ion maps were analyzed for comparison of signal intensity distributions. Results The precursor ion of tamoxifen ( m/z 372.233) displayed heterogeneous signal intensity distributions in histological compartments of tumor tissue sections. The levels of tamoxifen in tumor cells compared with stroma were higher in ER‐positive tissues, whereas ER‐negative tissue sections showed lower signal intensities in tumor cells. Conclusions The experimental model was successfully applied on frozen tumor samples allowing for differentiation between ER groups based on distribution of tamoxifen.